Dasatinib | 302962-49-8

Description :

Overview of Dasatinib

Dasatinib is a high-quality pharmaceutical tyrosine kinase inhibitor that is used as an active drug in targeted oncology treatments. The drug is a synthetic small-molecule drug created to block the multiple kinase pathways that are involved in the proliferation of cancer cells and survival.

In pharmaceutical manufacturing, Dasatinib is valued for its high potency, defined molecular structure, and suitability for oral solid dosage forms. It is produced under strictly controlled conditions to meet regulatory requirements for oncology APIs, including purity, polymorphic control, and impurity profiling.

As a pharma chemical, Dasatinib plays a critical role in modern targeted cancer treatment formulations.

Applications of Dasatinib

Pharmaceutical API & Oncology Formulations

Dasatinib is used as an active pharmaceutical ingredient in oral oncology formulations for targeted therapy. Its broad kinase inhibition profile supports use in advanced cancer treatment protocols requiring precise molecular targeting.

In oncology API development, it is often evaluated alongside Imatinib for comparative kinase inhibition profiles.

Pharmaceutical Chemistry & Functional Characteristics

From the perspective of a pharmaceutical chemist, Dasatinib is a thiazole-based drug with a great affinity to multiple Tyrosine Kinases. The molecular structure of the compound allows for strong binding to active and inactive kinase forms, which contributes to its effectiveness as a therapeutic agent.

These characteristics require precise control during synthesis and formulation to ensure consistent pharmacological performance.

Industrial & Regulated Manufacturing Use

Dasatinib is produced as a potent oncology API that has strict control of the parameters of synthesis, such as particle size, in addition to residual solvents. It is ideal for controlled pharmaceutical production facilities with special processing protocols.

In targeted oncology research, it may be referenced alongside compounds such as Bosutinib and Nilotinib for comparative formulation and therapeutic assessment.

Safety & Handling Guidelines

• Store in a cool, dry, and controlled environment
• Protect from light and moisture
• Keep containers tightly sealed and clearly labelled
• Avoid inhalation or direct contact during handling
• Make sure you have the appropriate personal protection equipment
• Controlled Oncology API production conditions
• The disposal of waste should be in line with the guidelines of the regulatory authorities.
  
  
  

Where to Buy Dasatinib?

Dasatinib Manufacturer

Dasatinib is manufactured for pharmaceutical oncology applications where controlled synthesis, high potency management, and regulatory compliance are essential.

Dasatinib Supplier & Distributor

Pharmaceutical-grade Dasatinib is supplied in suitable packaging for oncology formulation manufacturers. As a pharmaceutical chemicals supplier and distributor, Chemicalbull Pvt. Ltd. supports reliable sourcing with standard documentation.

MSDS for Dasatinib

The MSDS for Dasatinib provides detailed information on hazards, handling precautions, storage conditions, exposure controls, and emergency response measures. It should be reviewed before oncology API handling or formulation.

Frequently Asked Questions (FAQs)

1. What are the uses of Dasatinib?
   

   Dasatinib is used in pharmaceutical formulations for targeted oncology therapy involving tyrosine kinase inhibition.
   
   

2. What is the mechanism of action of Dasatinib?
   

   Dasatinib inhibits multiple tyrosine kinases involved in cancer cell growth and survival by blocking intracellular signalling pathways.
   
   

3. Are SPRYCEL and Dasatinib the same?
   

   SPRYCEL is the brand name under which dasatinib is marketed.
   
   

4. What are the side effects of Dasatinib?
   

   Dasatinib side effects may include haematological and gastrointestinal effects depending on dosage and treatment duration.
   
   

5. Bosutinib vs Dasatinib – how are they different?
   

   Both are tyrosine kinase inhibitors, but they differ in kinase selectivity and clinical application profiles.